Sobi receives FDA breakthrough designation for hemophilia drug

The US health authority has now awarded the Swedish firm three special statuses – the orphan drug, fast-track, and breakthrough therapy designations – for its hemophilia A treatment.
Photo: John Ambrose / Sobi / PR
Photo: John Ambrose / Sobi / PR
by christian bundgaard, translated by daniel pedersen

Swedish biotech firm Sobi has been granted the US Food and Drug Administration’s (FDA) breakthrough therapy designation for its drug candidate, efanesoctocog alfa, a potential treatment for bleeding disorder hemophilia A, the company has announced in a press release.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading